Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Accumulated Expenses: 2022-2024

Historic Accumulated Expenses for Gossamer Bio (GOSS) over the last 3 years, with Dec 2024 value amounting to $15.2 million.

  • Gossamer Bio's Accumulated Expenses rose 10.72% to $19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 million, marking a year-over-year increase of 10.72%. This contributed to the annual value of $15.2 million for FY2024, which is 43.08% down from last year.
  • Latest data reveals that Gossamer Bio reported Accumulated Expenses of $15.2 million as of FY2024, which was down 43.08% from $26.7 million recorded in FY2023.
  • Gossamer Bio's Accumulated Expenses' 5-year high stood at $26.7 million during FY2023, with a 5-year trough of $15.2 million in FY2024.
  • Over the past 3 years, Gossamer Bio's median Accumulated Expenses value was $20.5 million (recorded in 2022), while the average stood at $20.8 million.
  • As far as peak fluctuations go, Gossamer Bio's Accumulated Expenses increased by 29.94% in 2023, and later plummeted by 43.08% in 2024.
  • Yearly analysis of 3 years shows Gossamer Bio's Accumulated Expenses stood at $20.5 million in 2022, then rose by 29.94% to $26.7 million in 2023, then crashed by 43.08% to $15.2 million in 2024.